The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display variable sensitivity to therapeutics and may play different roles in progression. We previously characterized 2 cell populations in human breast tumors with distinct properties: CD44+CD24- cells that have stem cell-like characteristics, and CD44-CD24+ cells that resemble more differentiated breast cancer cells. Here we identified 15 genes required for cell growth or proliferation in CD44+CD24- human breast cancer cells in a large-scale loss-of-function screen and found that inhibition of several of these (IL6, PTGIS, HAS1, CXCL3, and PFKFB3) reduced Stat3 activation. We found that the IL-6/JAK2/Stat3 pathway was preferentially active in CD44+CD24- breast cancer cells compared with other tumor cell types, and inhibition of JAK2 decreased their number and blocked growth of xenografts. Our results highlight the differences between distinct breast cancer cell types and identify targets such as JAK2 and Stat3 that may lead to more specific and effective breast cancer therapies.

[1]  N. Nishimoto,et al.  Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. , 2006, Endocrine, metabolic & immune disorders drug targets.

[2]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Gönen,et al.  Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. , 2010, The Journal of clinical investigation.

[4]  Andrew J. Bannister,et al.  LIF independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease , 2010, Nature Cell Biology.

[5]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[6]  Jeannette Bigler,et al.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.

[7]  Y. Durocher,et al.  Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-β signaling , 2008, Oncogene.

[8]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[9]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[10]  J. Phillips,et al.  CXCR2 antagonists for the treatment of pulmonary disease. , 2009, Pharmacology & therapeutics.

[11]  T. Rosol,et al.  Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. , 2008, Cancer research.

[12]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[13]  M. Götte,et al.  Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. , 2006, Cancer research.

[14]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[15]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[16]  Suyun Huang,et al.  STAT3 as a central regulator of tumor metastases. , 2009, Current molecular medicine.

[17]  W. Vainchenker,et al.  JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. , 2008, Seminars in cell & developmental biology.

[18]  Jun Yao,et al.  Regulation of in situ to invasive breast carcinoma transition. , 2008, Cancer cell.

[19]  C. Maxwell,et al.  Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. , 2005, Current drug targets. Cardiovascular & haematological disorders.

[20]  Li Li,et al.  Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines* , 2002, The Journal of Biological Chemistry.

[21]  Stuart Gillies,et al.  Menadione-induced Reactive Oxygen Species Generation via Redox Cycling Promotes Apoptosis of Murine Pancreatic Acinar Cells* , 2006, Journal of Biological Chemistry.

[22]  J. Ritz,et al.  B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. , 1997, The Journal of clinical investigation.

[23]  M. Ringnér,et al.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.

[24]  Kevin Struhl,et al.  An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation , 2009, Cell.

[25]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Deblasio,et al.  JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. , 2011, Cancer cell.

[27]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[28]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[29]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[30]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[31]  Heike Knüpfer,et al.  Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.

[32]  Angel Porgador,et al.  Cell type-specific DNA methylation patterns in the human breast , 2008, Proceedings of the National Academy of Sciences.

[33]  Y. Wong,et al.  Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. , 2006, Cellular signalling.

[34]  V. Laporte,et al.  Novel role of CXCR2 in regulation of gamma-secretase activity. , 2008, ACS chemical biology.

[35]  D. Erdmann,et al.  Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 , 2010, Molecular Cancer Therapeutics.

[36]  Kornelia Polyak,et al.  Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer , 2010, Clinical Cancer Research.

[37]  Tatiana Nikolskaya,et al.  Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. , 2009, Methods in molecular biology.

[38]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[39]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[40]  M. Katsuki,et al.  STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells , 1999, The EMBO journal.

[41]  L. Bourguignon,et al.  Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells* , 2008, Journal of Biological Chemistry.

[42]  S. Vacher,et al.  CXC chemokines located in the 4q21 region are up-regulated in breast cancer. , 2007, Endocrine-related cancer.

[43]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[44]  P. Kuo,et al.  Osteopontin: regulation in tumor metastasis , 2008, Cancer and Metastasis Reviews.

[45]  Donna Spiegelman,et al.  Aspirin intake and survival after breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[47]  F. Greten,et al.  IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasis , 2009, EMBO reports.

[48]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[49]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[50]  N. Hacohen,et al.  Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[51]  Nir Hacohen,et al.  Genome-scale loss-of-function screening with a lentiviral RNAi library , 2006, Nature Methods.

[52]  M. Wicha.  Targeting breast cancer stem cells. , 2009, Breast.

[53]  A. Richardson,et al.  Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.

[54]  V. Ullrich,et al.  Purification and characterization of recombinant human prostacyclin synthase. , 2004, Journal of biochemistry.

[55]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[56]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[57]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[58]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[59]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[60]  Peter A Fasching,et al.  The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer , 2008, Breast Cancer Research.

[61]  L. Zon,et al.  Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis , 2007, Nature.

[62]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[63]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.